omeprazol

DRUG4 trials

Conditions

Biomarkers for Prediction of OA Treatment EfficacyConstipation-predominant Irritable Bowel SyndromeDiabetes Mellitus, Type 2Functional DyspepsiaKnee, Osteoarthritis (OA)Solid Tumor

Phase 1

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

CompletedNCT01585623

Bristol-Myers SquibbSolid Tumor

Start: 2012-06-30End: 2013-03-31Updated: 2025-03-05

Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes

TerminatedNCT04504045

University of Southern DenmarkDiabetes Mellitus, Type 2

Start: 2020-09-01End: 2022-05-10Updated: 2022-06-16

Phase 4

Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders

NCT05134584

RenJi HospitalConstipation-predominant Irritable Bowel Syndrome, Functional Dyspepsia

Start: 2021-01-01End: 2022-02-28Target: 78Updated: 2021-12-13

Unknown Phase

Biomarkers for Prediction of Analgesic Efficacy in Knee OA.

CompletedNCT05256342

Rambam Health Care CampusBiomarkers for Prediction of OA Treatment Efficacy, Knee, Osteoarthritis (OA)

Start: 2021-12-30End: 2024-04-08Updated: 2024-04-12

Related Papers

Efficacy of Linaclotide in Functional Dyspepsia and Constipation‐Predominant Irritable Bowel Syndrome Overlap: A Randomized Trial

Journal of Gastroenterology and Hepatology2025-03-133 citations

Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials